Raquel Sanches-Kuiper

Science and Technology Leader. Passionate developing disruptive technologies at the intersection of Biology, Engineering and AI with world-changing significance

[Mursla Bio @Mursla]

We are delighted to welcome Dr Raquel Sanches-Kuiper as Head of Research & Development at Mursla Bio. Raquel brings over 20 years of leadership experience in diagnostics, genomics and assay development, having most recently served as VP Science & Applications at Evonetix. There, she led multi-disciplinary teams across science and engineering, co-invented multiple patents, and played a key role in securing Series A and B funding. Earlier in her career at Solexa (later acquired by Illumina), Raquel helped establish the core molecular biology function and co-invented DNA polymerase technologies that were foundational to the company’s next-generation sequencing platform.

Raquel’s expertise in frontier omics research, technology transfer and commercial readiness will be instrumental as we advance towards the scale-up of our Dynamic Biopsy platform to support the clinical implementation of our flagship product, EvoLiverTM as well as developing our product pipeline. Her arrival marks another important step in our journey to transform clinical diagnostics through organ-specific extracellular vesicles.

#MurslaBio #ExtracellularVesicles #EVScience #Innovation #MultiOmics #DynamicBiopsy #LiquidBiopsy

[Mursla Bio @Mursla]

We are proud to announce that EvoLiver™, Mursla Bio’s flagship test for liver cancer surveillance, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).

The FDA awards Breakthrough Device Designation to a select number of medical devices that offer a more effective diagnosis of life-threatening diseases and represent a significant advancement over existing solutions. The Designation will support priority review, early feedback and more frequent FDA interactions to obtain FDA approved status for EvoLiver™, broadening its market reach and expediting commercial adoption.

This follows the announcement of our latest clinical results at AASLD Liver Meeting in San Diego, CA in which EvoLiver™ demonstrated 86% early-stage sensitivity at 88% specificity for liver cancer surveillance among cirrhotic, high-risk patients with diverse etiologies.

We are currently progressing towards the launch of EvoLiver™ as a Laboratory Developed Test (LDT), while also advancing our plans for FDA approval via the PMA pathway, which will enable broader clinical adoption and scale-up.

Check out our press release here: https://t.co/bTIJ1ETjnn

#FDA #BreakthroughDeviceDesignation #MurslaBio #EvoLiver #Diagnostics #EVscience #DynamicBiopsy #LiquidBiopsy

[Inside Precision Medicine @Inside_PM]

HCC Surveillance 2.0: FDA Recognizes @Mursla’s Extracellular Vesicle Test

EvoLiver's @US_FDA Breakthrough Device designation could swing liver #cancer surveillance tests from ultrasound to blood-based.
https://t.co/N6PUzWXYZt

[Mursla Bio @Mursla]

Last week our FDA Breakthrough Device Designation announcement was the most-read article on @GenomeWeb and @360DxNews – two of the most respected publications in the genomics and diagnostics space.

This recognition reflects the growing momentum around our mission to change the way we detect liver cancer and improve patient outcomes.

Our CEO, Pierre Arsène spoke to the editors about what this FDA milestone means for Mursla Bio, how we are using organ-specific EVs and multi-omics to shape the future of diagnostics and why our novel blood test EvoLiverTM could transform liver cancer surveillance for high risk individuals.

A big thank you to GenomeWeb and 360Dx for spotlighting our work – and to everyone who’s been following our journey.

Read the full articles here (paywall):

https://t.co/ZjSqkiWO2N

https://t.co/KZoDGQcjqF

#FDA #BreakthroughDeviceDesignation #LiverCancer #Diagnostics #GenomeWeb #360Dx #MurslaBio

[Mursla Bio @Mursla]

🎉 We are thrilled to share that Mursla Bio has been shortlisted for TWO awards at the 2025 Cambridge Independent (@CambridgeIndy) Science and Technology Awards – The Award for Innovation and MedTech Company of the Year!

Being recognised in Cambridge—one of the most vibrant and competitive biotech ecosystems in Europe and globally—is especially meaningful, and sets us on the right path globally as we prepare for our next phase of growth.

This recognition is a fantastic endorsement of our vision to transform liver cancer surveillance through EvoLiver™, our Dynamic Biopsy-based blood test powered by organ-specific hepatocyte extracellular vesicles.

Check out the full list of finalists:
https://t.co/z3ZLLAX3WO

#MurslaBio #CambridgeIndependent #ExtracellularVesicles #EVScience #MedTech #Innovation #LiquidBiopsy

[Raquel Sanches-Kuiper @RSanches_Kuiper]

❤️
https://t.co/aRxJavoaPR

#followyourdreams

[Raquel Sanches-Kuiper @RSanches_Kuiper]

https://t.co/iPraOzz4JS

[Ryan Bethencourt @RyanBethencourt]

Great talk panel with @johncumbers, @sean_os1, @Ryanphelan6 and @DrewEndy at the CEO lunch at @SynBioBeta

"We are suffering just now from a bad attack of economic pessimism." a great quote from Keynes by Drew Endy and he wanted us to explore what the optimistic future outlook for biology and biotech and what that will look like.

The physics of the future are starting to flourish!

[Raquel Sanches-Kuiper @RSanches_Kuiper]

Interesting review on #DNAsynthesis.

https://t.co/rEqlxH5OeI

[Raquel Sanches-Kuiper @RSanches_Kuiper]

Congratulations👏 ! I feel very privileged to have been part of that challenging but rewarding journey!

##dnasequencing #disruptiveinnovation

[Novo Nordisk Foundation @novonordiskfond]

Professors Sir David Klenerman and Sir Shankar Balasubramanian are being honoured with the 2024 Novo Nordisk Prize for their pioneering work, which enables the human genome to be sequenced in just an hour. This has opened the door to personalised healthcare and enhances our understanding of human diversity and disease. Photo: Nathan Pitt, University of Cambridge.
@novonordisk #Prize

https://t.co/72gis5AbYN

[Raquel Sanches-Kuiper @RSanches_Kuiper]

https://t.co/e988cRQ8nh
#InternationalWomensDay2024

[Frances Arnold @francesarnold]

We are thrilled to present a new #enzyme to the world, the first shown to break the man-made carbon-silicon bonds in #siloxanes, which are persistent in the environment.
https://t.co/BJOuWk4WGW

[Raquel Sanches-Kuiper @RSanches_Kuiper]

The power of WE helping each other and succeeding TOGETHER. To a better 2024 ❤️!

[Raquel Sanches-Kuiper @RSanches_Kuiper]

@Evonetix and @ADI_News agreement on the #semiconductor #chip development for our disruptive #genesynthesis #benchtop #platform to unlock the potential of #engineeringbiology in addressing the world's most urgent problems. #synbio #syntheticbiology #syntheticDNA

[Raquel Sanches-Kuiper @RSanches_Kuiper]

Reimagining #genesynthesis to unlock the power of #engineeringbiology #synbio # syntheticbiology @Evonetix

[Raquel Sanches-Kuiper @RSanches_Kuiper]

If you are at @SynbiCITE #SynbiTECH2023, don't miss @evonetix VP of Product @Mike_Daniels plenary presentation tomorrow morning # Reimagining #genesynthesis" #synbio #syntheticbiology #engineeringbiology

[Raquel Sanches-Kuiper @RSanches_Kuiper]

@Evonetix is reimagining #genesynthesis to further scale the field of #engineeringbiology #synbio #syntheticbiology and unleash the future of #healthcare

[Raquel Sanches-Kuiper @RSanches_Kuiper]

#syntheticDNA #engineeringbiology #synbio #genesynthesis

[Drug Discovery World @DDWJournal]

Unlocking the potential of synthetic DNA

https://t.co/RAn6j477bj

#SyntheticDNA

[SynBioBeta @SynBioBeta]

U.K. approves world’s first #CRISPR-based medicine, giving greenlight to therapy for sickle cell, thalassemia: https://t.co/y1XUuaZKU4

[SynBioBeta @SynBioBeta]

#CRISPR-Based Therapy Receives Regulatory Green Light in the UK: https://t.co/8hLSBUnj9i